Amendments to the Claims:

Claims 1-20 (Canceled)

21. (Currently amended) A pharmaceutical composition for the reduction of pain upon injection, said composition comprising human insulin-like growth factor 1 (IGF-I) and a buffer, wherein said buffer consists substantially of succinate at a concentration of about 10 mM to about 40 mM and a counterion.

22. (Previously presented) The composition of claim 21, wherein said counterion is selected from the group consisting of sodium, potassium, ammonium, and said IGF-I.

23. (Previously presented) The composition of claim 21, wherein the concentration of succinate is about 10 mM to about 30 mM.

24. (Previously presented) The composition of claim 23, wherein the concentration of succinate is about 10 mM to about 20 mM.

25. (Previously presented) The composition of claim 24, wherein the concentration of succinate is about 10 mM.

26. (Previously presented) The composition of claim 21, wherein said composition has a pH of about 4.0 to about 7.0.

27. (Previously presented) The composition of claim 26, wherein said pH is about 4.6 to about 6.6.

28. (Previously presented) The composition of claim 27, wherein said pH is about 6.0.

29. (Previously presented) The composition of claim 21, further comprising a sufficient concentration of a tonicifying agent such that the composition is isotonic.

30. (Previously presented) The composition of claim 29, wherein said tonicifying agent is sodium chloride.

31. (Previously presented) The composition of claim 21, wherein said human IGF-I is recombinant human IGF-I.

32. (Previously presented) The composition of claim 31, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

33. (Previously presented) The pharmaceutical composition of claim 21, wherein said composition is a liquid.

34. (Previously presented) The pharmaceutical composition of claim 21, wherein said composition is lyophilized.

Claims 35-44 (Canceled)

45. (Currently amended) A sterile injectable pharmaceutical composition <u>for the reduction of pain upon injection, said composition</u> comprising human insulin-like growth factor I (IGF-I) or a biologically active variant thereof and a buffer, wherein said buffer consists substantially of succinate at a concentration of 7 mM to 45 mM and a counterion, wherein said variant is a polypeptide having IGF-I activity and at least 70% sequence identity to human IGF-I.

46. (Previously presented) The composition of claim 45, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

Claims 47-52 (Canceled)